Stonepine Capital Management LLC Trims Stake in PolyPid Ltd. (NASDAQ:PYPD)

Stonepine Capital Management LLC reduced its stake in shares of PolyPid Ltd. (NASDAQ:PYPD) by 25.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 103,668 shares of the company’s stock after selling 34,836 shares during the quarter. Stonepine Capital Management LLC’s holdings in PolyPid were worth $315,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Rosalind Advisors Inc. raised its position in PolyPid by 49.9% during the fourth quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after acquiring an additional 338,853 shares in the last quarter. J. Goldman & Co LP acquired a new stake in PolyPid in the fourth quarter valued at approximately $391,000. Finally, AIGH Capital Management LLC grew its holdings in PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after purchasing an additional 148,199 shares during the period. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Stock Performance

Shares of NASDAQ:PYPD opened at $2.74 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. The business’s 50 day moving average price is $2.73 and its 200-day moving average price is $2.98. The firm has a market capitalization of $27.92 million, a PE ratio of -0.55 and a beta of 1.25. PolyPid Ltd. has a 1 year low of $2.30 and a 1 year high of $4.71.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.10. As a group, equities research analysts expect that PolyPid Ltd. will post -1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on PYPD. Rodman & Renshaw began coverage on PolyPid in a report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of PolyPid in a report on Monday, April 14th. Finally, RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th.

PolyPid Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.